4K4 Stock Overview
Develops injectable treatment for chronic pain triggered by disc degeneration.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Stayble Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.059 |
| 52 Week High | SEK 0.49 |
| 52 Week Low | SEK 0.017 |
| Beta | 0.26 |
| 11 Month Change | -12.52% |
| 3 Month Change | 168.78% |
| 1 Year Change | -84.77% |
| 33 Year Change | -91.95% |
| 5 Year Change | n/a |
| Change since IPO | -92.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4K4 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 23.5% | -0.8% | -1.0% |
| 1Y | -84.8% | -11.6% | 12.8% |
Return vs Industry: 4K4 underperformed the German Pharmaceuticals industry which returned -11.6% over the past year.
Return vs Market: 4K4 underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| 4K4 volatility | |
|---|---|
| 4K4 Average Weekly Movement | 18.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4K4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4K4's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2 | Andreas Gerward | www.staybletherapeutics.se |
Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration. The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Stayble Therapeutics AB (publ) Fundamentals Summary
| 4K4 fundamental statistics | |
|---|---|
| Market cap | €2.78m |
| Earnings (TTM) | -€1.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs 4K4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4K4 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 20.40m |
| Earnings | -SEK 20.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.0% |
How did 4K4 perform over the long term?
See historical performance and comparison